By Nello Mainolfi, PhD, Co-Founder, President and CEO of Kymera Therapeutics, as part of the From The Trenches feature of LifeSciVC. The inherent ability to combine the power of genetic-like knockdown with the flexibility of small molecules; the power to

By Aoife Brennan, CEO of Synlogic, as part of the From The Trenches feature of LifeSciVC I was in the passenger seat, trying desperately not to reach for the grab handle, saying reassuring things but thinking ‘those mailboxes are really

By Andrea DiMella, VP and Head of Talent at Atlas Venture, as part of the From The Trenches feature of LifeSciVC Spring in New England is in full bloom. All around birds are chirping, flowers are blooming, and there is

The universe of public biotech companies has been growing for a decade, and increasingly so in the past few years as the IPO market has flourished. Hundreds of young aspiring biotechs have tapped into the public equity markets, swelling the

The biotech job market is a bit like the suburban housing market—red hot. It’s a buyer’s market, don’t waive your inspection rights! By Pamela L. Esposito, CBO of Replimune as part of the From The Trenches feature of LifeSciVC. It

Co-authored by Jodie Morrison and René Russo, former CEO of Cadent Therapeutics and CEO of Xilio Therapeutics, respectively.   Over the last 5 years, biotech executives have been increasingly focused on the importance of greater diversity in our companies. As two

By Deanna Petersen, Chief Business Officer of AVROBIO, as part of the From The Trenches feature of LifeSciVC Most of the titles in a biotech C-suite are generally self-explanatory. The Chief Technical and Manufacturing Officer runs operations in CMC and

The role of the core in making an organization great and how we do right by them By Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC Small organizations are amazing for the

Despite saving the world from COVID, pharma and biotech are still in the crosshairs of many politicians. With many anti-Pharma politicians and regulators emboldened in the current environment, and with more aggressive tax and spending policy in the works, there

Another quarter, another set of all-time highs for biotech funding – and this surfeit of capital continues raises possible concerns about its disciplined deployment. Back in January, when reflecting on the strange paradox of 2020, all-time-highs were across the board:

By Jonathan Montagu, CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC Returning to work following the pandemic presents an opportunity to think creatively about how to re-configure the workplace.  CEO’s that I have spoken

By Joshua Brumm, CEO of Dyne Therapeutics, as part of the From The Trenches feature of LifeSciVC I’ve been thinking a lot about growth, and for good reason: Dyne is in the midst of a significant scale-up. We expanded our